KIAA1166 Inhibitors
KIAA1166 inhibitors encompass a range of chemical compounds that exert their effects through various biochemical pathways, ultimately leading to the inhibition of KIAA1166's functional activity. By targeting upstream components in signaling cascades, these inhibitors can indirectly suppress the activity of KIAA1166, presuming that KIAA1166 acts downstream of these pathways. For instance, compounds that inhibit key kinases in the MAPK/ERK pathway prevent the phosphorylation and subsequent activation of downstream effectors, which would include KIAA1166 given it is a part of this signaling network. Similarly, inhibitors of PI3K or mTOR would thwart the activation of downstream proteins involved in cell growth and survival, thus reducing KIAA1166 activity if it were implicated in these processes. The specificity of these inhibitors for their respective targets ensures that the impact on KIAA1166 is a result of precise blockade of these signaling avenues rather than off-target effects.
Furthermore, the repertoire of KIAA1166 inhibitors includes molecules that interfere with protein stability and cytoskeletal organization. Proteasome inhibitors, for example, induce the accumulation of proteins targeted for degradation, which could affect KIAA1166 if its regulation is dependent on proteasomal turnover. Inhibitors of the Hedgehog pathway or BMP signaling also play a role, as they could impact KIAA1166's activity by modulating developmental pathways that it may be involved in. Compounds that affect the actin cytoskeleton through the inhibition of ROCK kinase may also lead to decreased KIAA1166 activity assuming it is associated with cellular structures or motility.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin is an mTOR inhibitor that suppresses cell growth and proliferation. Given KIAA1166 is involved in mTOR signaling, rapamycin would reduce KIAA1166 activity by inhibiting the pathway upstream. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY 294002 is a PI3K inhibitor that prevents the phosphorylation and activation of PI3K-dependent signaling. Given KIAA1166 functions downstream of PI3K, then LY 294002 would lead to decreased KIAA1166 activity by inhibiting its upstream signaling. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB 203580 is a p38 MAPK inhibitor that impedes the p38 MAPK signaling pathway. Should KIAA1166 be a downstream effector of p38 MAPK, its activity would be reduced following the inhibition of this kinase. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD 98059 is a MEK inhibitor that blocks the activation of MAPK/ERK pathway. If KIAA1166 operates within this pathway, its activity would be indirectly inhibited through prevention of upstream signaling. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Bortezomib is a proteasome inhibitor that leads to the accumulation of misfolded proteins, thus affecting proteins like KIAA1166 if it relies on proteasome-mediated degradation for its regulation. | ||||||
Cyclopamine | 4449-51-8 | sc-200929 sc-200929A | 1 mg 5 mg | $94.00 $208.00 | 19 | |
Cyclopamine is a Hedgehog pathway inhibitor that binds to and inhibits Smoothened. If KIAA1166 is part of the Hedgehog signaling cascade, its activity would be diminished by this upstream inhibition. | ||||||
GW 5074 | 220904-83-6 | sc-200639 sc-200639A | 5 mg 25 mg | $106.00 $417.00 | 10 | |
GW 5074 is a RAF kinase inhibitor that impedes the MAPK/ERK signaling. If the function of KIAA1166 is modulated by RAF kinase activity, then GW 5074 would lead to decreased KIAA1166 activity by blocking the upstream signal transduction. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is a highly selective inhibitor of both MEK1 and MEK2. If KIAA1166 functions downstream of MEK, inhibition by U0126 would result in decreased KIAA1166 activity. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is a JNK inhibitor that blocks JNK signaling. If KIAA1166 is regulated by JNK signaling pathways, SP600125 would lead to its decreased activity by inhibiting upstream signals. | ||||||
WZ 4002 | 1213269-23-8 | sc-364655 sc-364655A | 10 mg 50 mg | $180.00 $744.00 | 1 | |
WZ 4002 is a selective EGFR inhibitor, particularly against EGFR mutations. If KIAA1166 activity is EGFR-dependent, then WZ 4002 would decrease its activity by inhibiting this upstream tyrosine kinase. | ||||||